Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.41 |
| ▸ | PRKACA | P17612 | 3/20 | 0.41 |
| ▸ | PRKG1 | Q13976 | 3/20 | 0.41 |
| ▸ | PRKACG | P22612 | 2/20 | 0.41 |
| ▸ | PRKACB | P22694 | 2/20 | 0.41 |
| ▸ | AKT1 | P31749 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | CTSA | P10619 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29691431 | 1.00 | ROCK2 (0.41) | ROCK2ROCK1PRKACAPRKG1PRKACG | |
| SCHEMBL29757378 | 0.91 | ROCK2 (0.36) | ROCK2ROCK1PRKACAPRKG1PRKACG | |
| SCHEMBL23013492 | 0.89 | ROCK2 (0.45) | ROCK2ROCK1PRKACAPRKG1PRKACG | |
| SCHEMBL29691436 | 0.87 | CTSA (0.42) | ROCK2ROCK1PRKACAPRKG1PRKACG | |
| SCHEMBL23012645 | 0.87 | CTSA (0.42) | ROCK2ROCK1PRKACAPRKG1PRKACG | |
| SCHEMBL21962081 | 0.86 | NLRP3 (0.46) | CYP3A4LPAR1NLRP3CTSA | |
| SCHEMBL23012260 | 0.84 | SMN1; SMN2 (0.44) | ROCK2ROCK1PRKACAPRKG1PRKACG | |
| SCHEMBL29691441 | 0.84 | SMN1; SMN2 (0.44) | ROCK2ROCK1PRKACAPRKG1PRKACG | |
| SCHEMBL23012235 | 0.81 | ROCK2 (0.40) | ROCK2ROCK1PRKACAPRKG1PRKACG | |
| SCHEMBL29691382 | 0.81 | ROCK2 (0.40) | ROCK2ROCK1PRKACAPRKG1PRKACG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389031-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-12-08 | — | — | US | disclosed |
| US-20220389031-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-12-08 | — | — | US | disclosed |
| EP-4013762-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | Inflazome Limited (IE) | 2022-06-22 | — | — | EP | disclosed |
| CN-114555609-A | Macrocyclic sulfonamide derivatives useful as NLRP3 inhibitors | 英夫拉索姆有限公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021032588-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032588-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389031-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | NLRP3, NOD1, PYCARD | ROCK2 4438/4885ROCK1 4337/4885PRKACA 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.